- Home
- IONS vs TFII Comparison
IONS vs TFII Comparison
Compare IONS & TFII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- TFII
- Stock Information
- Founded
- IONS 1989
- TFII 1957
- Country
- IONS United States
- TFII Canada
- Employees
- IONS N/A
- TFII N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- TFII Trucking Freight/Courier Services
- Sector
- IONS Health Care
- TFII Industrials
- Exchange
- IONS Nasdaq
- TFII Nasdaq
- Market Cap
- IONS 6.9B
- TFII 7.5B
- IPO Year
- IONS 1991
- TFII N/A
- Fundamental
- Price
- IONS $43.78
- TFII $90.68
- Analyst Decision
- IONS Buy
- TFII Buy
- Analyst Count
- IONS 14
- TFII 11
- Target Price
- IONS $58.43
- TFII $119.27
- AVG Volume (30 Days)
- IONS 2.0M
- TFII 449.0K
- Earning Date
- IONS 07-30-2025
- TFII 07-28-2025
- Dividend Yield
- IONS N/A
- TFII 1.93%
- EPS Growth
- IONS N/A
- TFII N/A
- EPS
- IONS N/A
- TFII 4.34
- Revenue
- IONS $944,050,000.00
- TFII $8,263,477,999.00
- Revenue This Year
- IONS $9.21
- TFII N/A
- Revenue Next Year
- IONS $14.35
- TFII $4.46
- P/E Ratio
- IONS N/A
- TFII $20.47
- Revenue Growth
- IONS 16.05
- TFII 3.10
- 52 Week Low
- IONS $23.95
- TFII $72.02
- 52 Week High
- IONS $50.43
- TFII $155.12
- Technical
- Relative Strength Index (RSI)
- IONS 60.61
- TFII 52.94
- Support Level
- IONS $40.37
- TFII $83.43
- Resistance Level
- IONS $41.93
- TFII $93.31
- Average True Range (ATR)
- IONS 1.42
- TFII 2.95
- MACD
- IONS -0.03
- TFII 0.33
- Stochastic Oscillator
- IONS 66.61
- TFII 58.19
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About TFII TFI International Inc.
TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customers' specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.